Latest News From Lumira Ventures

Zymeworks Announces Closing of US$320.8M Public Offering

Jennifer Schram Portfolio News, Press Release, Zymeworks

VANCOUVER, British Columbia–(BUSINESS WIRE)– Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics (“Zymeworks” or the “Company”), announced today the closing of its previously announced underwritten public offering (the “Offering”). The Offering consisted of 5,824,729common shares, including the …

Zymeworks Files Preliminary Prospectus Supplements for Offering of Common Shares and Pre-Funded Warrants

Jennifer Schram Portfolio News, Press Release, Zymeworks

VANCOUVER, British Columbia—(BUSINESS WIRE)– Zymeworks Inc. (NYSE: ZYME) (“Zymeworks” or the “Company”), a clinical‑stage biopharmaceutical company developing multifunctional biotherapeutics, has today filed a preliminary prospectus supplement (the “Canadian Supplement”) to its Canadian short form base shelf prospectus dated November 18, …

Zymeworks Inks Collaboration Agreement with Pfizer in Breast Cancer Study

Jennifer Schram Portfolio News, Press Release, Zymeworks

VANCOUVER, British Columbia–(BUSINESS WIRE)– Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced the initiation of a Phase 2 trial evaluating ZW25 combination therapy and an agreement with Pfizer which advances the study. Zymeworks’ HER2-targeted bispecific …

Zymeworks Announces Updated Single Agent Data for HER2-Targeted Bispecific Antibody ZW25 at ESMO Congress 2019

Jennifer Schram Portfolio News, Press Release, Zymeworks

BARCELONA, Spain–(BUSINESS WIRE) — Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced updated data from the ongoing multi-center Phase 1 clinical trial evaluating ZW25 in patients with HER2‑expressing solid tumors, including biliary tract cancer (BTC), …

Zymeworks Releases Q2 2019 Financial Results

Jennifer Schram Portfolio News, Press Release, Zymeworks

Related Article: Zymeworks Reports 2019 First Quarter Results VANCOUVER, British Columbia–(BUSINESS WIRE)– Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the second quarter ended June 30, 2019. “We had a notable second …

Celgene Exercises Commercial Option for Zymeworks’ Azymetric™ Platform Triggering $7.5MM Milestone Payment

Jennifer Schram Portfolio News, Press Release, Zymeworks

VANCOUVER, British Columbia–(BUSINESS WIRE) — Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that its global biopharma partner Celgene Corporation has selected a lead therapeutic candidate in oncology for further development and exercised its option …